Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
GTP-Binding Protein alpha Subunits, Gi-Go
A family of heterotrimeric GTP-binding protein alpha subunits that were originally identified by their ability to inhibit ADENYLYL CYCLASES. Members of this family can couple to beta and gamma G-protein subunits that activate POTASSIUM CHANNELS. The Gi-Go part of the name is also spelled Gi/Go.
Year introduced: 2004(1997)
Gastrointestinal Transit
Passage of food (sometimes in the form of a test meal) through the gastrointestinal tract as measured in minutes or hours. The rate of passage through the intestine is an indicator of small bowel function.
Year introduced: 1988
farglitazar [Supplementary Concept]
a non-thiazolidinedione insulin sensitiser and PPARgamma agonist
Date introduced: March 23, 2001
conotoxin GI [Supplementary Concept]
highly toxic; from venom of marine snail Conus geographus; amino acid sequence given in first source
Date introduced: June 24, 1981
Gastrointestinal Tract
Generally refers to the digestive structures stretching from the MOUTH to ANUS, but does not include the accessory glandular organs (LIVER; BILIARY TRACT; PANCREAS).
Year introduced: 2004
Upper Gastrointestinal Tract
The segment of GASTROINTESTINAL TRACT that includes the ESOPHAGUS; the STOMACH; and the DUODENUM.
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.
Year introduced: 1995
Gastrointestinal Contents
The contents included in all or any segment of the GASTROINTESTINAL TRACT.
Year introduced: 2004 (1985)
3-(formylhydroxyamino)-2-(3-phenyl-1-propyl)butanoic acid (2,2-dimethyl-1-methylcarbamoyl-1-propyl)amide [Supplementary Concept]
an ADAM10 inhibitor and antineoplastic agent; structure in first source
Date introduced: January 30, 2011
GI 5005 [Supplementary Concept]
based on HCV NS3-core fusion protein
Date introduced: November 3, 2009
GI 181771X [Supplementary Concept]
Date introduced: August 24, 2004
GI 0122 [Supplementary Concept]
a CCK1 receptor agonist; structure in first source
Date introduced: August 23, 2003
GI 5269 [Supplementary Concept]
GPX2 protein, human [Supplementary Concept]
a selenoenzyme expressed exclusively in gastrointestinal tract; RefSeq NM_002083
Date introduced: March 2, 1999
Equid herpesvirus 1 gl [Supplementary Concept]
EHV-1 a member of the Alphaherpesvirus subfamily; amino acid sequence in first source; GenBank M86664 (Ab4P) and U13845 (pCH110)
Date introduced: April 2, 1998
lamivudine sulfoxide [Supplementary Concept]
urinary metabolite of lamivudine
Date introduced: March 28, 1997
GI 168 [Supplementary Concept]
a matrix metalloproteinase inhibitor
Date introduced: September 6, 1995
GI 149893 [Supplementary Concept]
structure given in first source
Date introduced: February 27, 1995
lurtotecan [Supplementary Concept]
NX-211 is the low-clearance liposomal formulation; structure in first source
GI 129471 [Supplementary Concept]
metalloprotease inhibitor that blocks TNF-alpha secretion; structure given in first source
Date introduced: September 2, 1994